In this free webinar, learn how vascular phenotyping can be included in the design of clinical trials, and how new digital health technologies that capture biomarkers of vascular disease can be used to determine the efficacy of emerging therapies. Attendees will gain insights into how vascular phenotyping enables non-invasive identification of subclinical disease, risk stratification and therapeutic monitoring. The featured speaker will discuss how key techniques like arterial stiffness indices and endothelial function assessments enhance clinical trials, supporting personalized treatments and predictive outcomes. The speaker will also share how vascular phenotyping drives innovation in patient care and therapeutic development.
TORONTO, March 25, 2025 /PRNewswire-PRWeb/ -- Vascular phenotyping has emerged as an important tool in advancing our understanding of chronic diseases. By providing non-invasive, digital biomarkers of vascular function phenotyping enables an early identification of subclinical disease and a more precise approach to risk stratification and therapeutic effectiveness. Key modalities, including arterial stiffness indices, endothelial function assessments and advanced imaging techniques, offer insights from early vascular changes through the spectrum of vascular disease and cardiovascular events, including myocardial infarction and stroke.
Incorporating vascular phenotyping into clinical trials enhances the mechanistic understanding of investigational therapies, facilitates personalized treatment approaches and strengthens the predictive value of trial outcomes. It is particularly important in studies targeting cardiovascular, respiratory, renal and metabolic diseases as well as in women's health and in various ethnicities where vascular changes is both a mediator and a marker of disease progression.
As precision medicine continues to evolve, vascular phenotyping serves as an indispensable bridge between research and clinical application, ultimately improving patient care and therapeutic innovation.
Register for this webinar today to explore how vascular phenotyping can be included in the design of clinical trials, and how new digital health technologies that capture biomarkers of vascular disease can be used to determine the efficacy of emerging therapies.
Join Dr. Sanjeev Bhavnani, MD FACC, Chief Clinical Officer, Cardiex, for the live webinar on Monday, April 14, 2025, at 1pm EDT (10am PDT).
For more information, or to register for this event, visit Vascular Phenotyping: A New Paradigm in Drug Development.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
SOURCE Xtalks
Share this article